AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis' branded respiratory business in the US and Canada. As previously announced, the strategic transaction strengthens AstraZeneca's respiratory franchise globally and builds on the acquisition of Almirall's respiratory portfolio in 2014
Novartis announces completion of transactions with GSK
- Details
- Category: Novartis
Novartis announced today that it has completed a series of transactions with GlaxoSmithKline plc (GSK), including the acquisition of certain oncology products and pipeline compounds from GSK, the creation of a world-leading consumer healthcare business through a joint venture that combines the two companies' consumer divisions, and the divestiture of the Novartis non-influenza Vaccines business to GSK.
Shire acquires Meritage Pharma
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.
Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
- Details
- Category: Novartis
Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat, previously known as LBH589) capsules in combination with bortezomib* and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory (IMiD) agent[1].
Sanofi and Lead Pharma to develop treatments for autoimmune diseases
- Details
- Category: Sanofi
Sanofi announced today that it has entered into a research collaboration and license agreement with Dutch biotech Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common.
GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
- Details
- Category: GlaxoSmithKline
GSK has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and has now acquired the remaining shares for US $190 million (approximately £124 million) in cash to take full ownership of the company.
Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the acquisition of Signature Diagnostics AG (Signature), a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies.
More Pharma News ...
- Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study
- Pfizer to Acquire Hospira
- AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
- Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
- AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
- Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results
- Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial